CDT Equity Inc. Warrant
CDTTW
About: CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Employees: 6
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
209% more capital invested
Capital invested by funds: $243K [Q1] → $752K (+$509K) [Q2]
1.42% less ownership
Funds ownership: 5.7% [Q1] → 4.29% (-1.42%) [Q2]
15% less funds holding
Funds holding: 20 [Q1] → 17 (-3) [Q2]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Financial journalist opinion
We haven’t received any recent news articles for CDTTW